Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs
- PMID: 4717022
- PMCID: PMC1776517
- DOI: 10.1111/j.1476-5381.1973.tb08160.x
Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs
Abstract
1. Effects of inhibitors of DOPA decarboxylase, dopamine beta-hydroxylase and monoamine oxidase, and haloperiodol on the secretion of pancreatic juice induced by L-DOPA and dopamine were studied in preparations of the isolated blood-perfused canine pancreas.2. The increased secretion induced by the infusion of L-DOPA (100 mug/min) was completely antagonized by Ro 4-4602 (300 mug), a DOPA decarboxylase inhibitor.3. The secretogogue effect of dopamine (1-10 mug) intra-arterially was not affected by Ro 4-4602, but was enhanced by the infusion of fusaric acid (100 mug/min), a dopamine beta-hydroxylase inhibitor.4. The increase in the secretion induced by dopamine (1-10 mug) was enhanced by treatment with nialamide (100 mg/kg), a monoamine oxidase inhibitor, given intravenously.5. Haloperidol (1 mg) intra-arterially attenuated the dopamine-induced pancreatic secretion.6. It is concluded that L-DOPA is converted to dopamine in the acinar cells which causes an increase in the secretion of pancreatic juice, thus the intracellular level of dopamine may be controlled by enzymatic equilibrium.
Similar articles
-
Effect of dopamine on pancreatic secretion in the dog.Br J Pharmacol. 1971 Dec;43(4):739-46. doi: 10.1111/j.1476-5381.1971.tb07209.x. Br J Pharmacol. 1971. PMID: 5152026 Free PMC article.
-
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.J Pharmacol Exp Ther. 1976 Feb;196(2):380-8. J Pharmacol Exp Ther. 1976. PMID: 1255483
-
Enhancement of dopamine-induced stimulation of pancreatic secretion by 5-dimethyldithiocarbamylpicolinic acid (YP-279), a dopamine beta-hydroxylase inhibitor.Jpn J Pharmacol. 1979 Apr;29(2):187-90. doi: 10.1254/jjp.29.187. Jpn J Pharmacol. 1979. PMID: 537244
-
Central actions of dopa and dopamine.Rev Can Biol. 1972;31:Suppl:153-68. Rev Can Biol. 1972. PMID: 4403289 Review. No abstract available.
-
Aggression and central neurotransmitters.Int Rev Neurobiol. 1975;18:213-62. doi: 10.1016/s0074-7742(08)60036-7. Int Rev Neurobiol. 1975. PMID: 1353 Review. No abstract available.
Cited by
-
Dopamine-induced amylase secretion from guinea-pig submandibular gland.Br J Pharmacol. 1975 Aug;54(4):523-8. doi: 10.1111/j.1476-5381.1975.tb07600.x. Br J Pharmacol. 1975. PMID: 169937 Free PMC article.
-
Modification by drugs of the secretagogue effect of dopamine on the pancrease.Br J Pharmacol. 1974 Jun;51(2):225-30. doi: 10.1111/j.1476-5381.1974.tb09651.x. Br J Pharmacol. 1974. PMID: 4615760 Free PMC article.
-
L-Dopa inhibits metoclopramide stimulation of the lower esophageal sphincter in man.Dig Dis Sci. 1979 Apr;24(4):289-95. doi: 10.1007/BF01296543. Dig Dis Sci. 1979. PMID: 378623 Clinical Trial.
-
Action of dopamine on the exocrine pancreatic secretion of the intact dog.Br J Pharmacol. 1986 May;88(1):189-95. doi: 10.1111/j.1476-5381.1986.tb09486.x. Br J Pharmacol. 1986. PMID: 2871881 Free PMC article.
-
Haloperidol, a dopaminergic antagonist: somatostatin-like inhibition of glucagon and insulin release from the isolated, perfused canine pancreas.Diabetologia. 1978 Oct;15(4):343-7. doi: 10.1007/BF03161000. Diabetologia. 1978. PMID: 710756
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials